1373 studies found for:    Open Studies | "Lymphoma"
Show Display Options
Rank Status Study
21 Recruiting Combination Chemotherapy or 90-Yttrium Ibritumomab Tiuxetan and Combination Chemotherapy Before Stem Cell Transplant in Treating Patients With Relapsed Diffuse Large B-cell Non-Hodgkin Lymphoma
Conditions: Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
Interventions: Radiation: Yttrium Y 90 Ibritumomab tiuxetan;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Biological: Rituximab;   Procedure: Peripheral Blood Stem Cell Transplantation;   Other: Laboratory Biomarker Analysis
22 Recruiting Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas
Conditions: Follicular Lymphomas;   Immunocytomas;   Marginal Zone Lymphomas;   Mantle-Cell Lymphomas;   Lymphocytic Lymphoma;   Non-Hodgkin's Lymphoma
Interventions: Drug: Rituximab;   Drug: Rituximab / observation
23 Recruiting Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas
Conditions: Lymphoma, T-Cell, Cutaneous;   Lymphoma, T-Cell, Peripheral;   Hodgkin Disease;   Lymphoma, Large B-Cell, Diffuse
Interventions: Drug: Romidepsin;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Dexamethasone;   Drug: Pegfilgrastim
24 Recruiting Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas
Conditions: Adult Grade III Lymphomatoid Granulomatosis;   AIDS-Related Diffuse Large Cell Lymphoma;   HIV Infection;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Adult Contiguous Immunoblastic Lymphoma;   Stage II Adult Non-Contiguous Immunoblastic Lymphoma;   Stage II Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Contiguous Adult Diffuse Mixed Cell Lymphoma;   Stage II Contiguous Adult Lymphoblastic Lymphoma;   Stage II Contiguous Mantle Cell Lymphoma;   Stage II Grade 3 Contiguous Follicular Lymphoma;   Stage II Grade 3 Non-Contiguous Follicular Lymphoma;   Stage II Non-Contiguous Adult Diffuse Large Cell Lymphoma;   Stage II Non-Contiguous Adult Diffuse Mixed Cell Lymphoma;   Stage II Non-Contiguous Adult Lymphoblastic Lymphoma;   Stage II Non-Contiguous Mantle Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate;   Drug: Vorinostat
25 Recruiting Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
Conditions: Hematopoietic/Lymphoid Cancer;   Adult Acute Lymphoblastic Leukemia in Remission;   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
Interventions: Biological: anti-CD20-CAR vector-transduced autologous T cells;   Other: genetically engineered lymphocyte therapy
26 Not yet recruiting Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Peripheral/Systemic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   Stage III AIDS-related Lymphoma;   Stage IV AIDS-related Lymphoma
Interventions: Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Drug: lomustine;   Drug: etoposide;   Drug: procarbazine hydrochloride;   Other: laboratory biomarker analysis
27 Recruiting High-Dose Y-90-Ibritumomab Tiuxetan Added to Reduced-Intensity Allogeneic Stem Cell Transplant Regimen for Relapsed or Refractory Aggressive B-Cell Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Post-transplant Lymphoproliferative Disorder;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma
Interventions: Radiation: indium In 111 ibritumomab tiuxetan;   Radiation: yttrium Y 90 ibritumomab tiuxetan;   Biological: rituximab;   Radiation: total-body irradiation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: pharmacological study
28 Recruiting Study of Brentuximab Vedotin Combined With RCHOP or RCHP in Front-line Treatment of Patients With Diffuse Large B-cell Lymphoma (DLBCL)
Conditions: Lymphoma, B-cell;   Lymphoma, Large B-cell, Diffuse
Interventions: Drug: brentuximab vedotin;   Drug: rituximab;   Drug: vincristine;   Drug: cyclophosphamide;   Drug: prednisone;   Drug: doxorubicin
29 Recruiting Pembrolizumab After ASCT for Hodgkin Lymphoma and DLBCL
Conditions: Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma
Intervention: Drug: Pembrolizumab
30 Recruiting TLR9 Agonist SD-101, Ipilimumab, and Radiation Therapy in Treating Patients With Low-Grade Recurrent B-cell Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Splenic Marginal Zone Lymphoma
Interventions: Biological: ipilimumab;   Drug: TLR9 agonist SD-101;   Radiation: radiation therapy;   Other: laboratory biomarker analysis
31 Recruiting R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B
Conditions: Diffuse Large B-cell Lymphoma;   Follicular Lymphoma Grade 3B
Interventions: Drug: R-CEOP-70;   Drug: R-CEOP-90;   Drug: R-CHOP-50
32 Recruiting Brentuximab Vedotin and Bendamustine for the Treatment of Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma (ALCL)
Conditions: Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma
Interventions: Drug: Brentuximab Vedotin;   Drug: Bendamustine;   Drug: Neulasta
33 Recruiting Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma
Conditions: Follicular Lymphoma;   Mantle Cell Lymphoma
Intervention: Drug: Temsirolimus, Rituximab, Bendamustin
34 Recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma
Conditions: AIDS-related Diffuse Large Cell Lymphoma;   AIDS-related Diffuse Mixed Cell Lymphoma;   AIDS-related Diffuse Small Cleaved Cell Lymphoma;   AIDS-related Immunoblastic Large Cell Lymphoma;   AIDS-related Lymphoblastic Lymphoma;   AIDS-related Small Noncleaved Cell Lymphoma;   HIV Infection
Interventions: Drug: busulfan;   Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells;   Other: pharmacological study;   Other: laboratory biomarker analysis
35 Recruiting CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for Newly Diagnosed Young Patients With T Cell Lymphoma
Conditions: ALK-negative Anaplastic Large Cell Lymphoma;   Peripherial T Cell Lymphoma,Not Otherwise Specified;   Angioimmunoblastic T Cell Lymphoma;   Enteropathy Associated T Cell Lymphoma;   Hepatosplenic T Cell Lymphoma;   Subcutaneous Panniculitis Like T Cell Lymphoma
Interventions: Drug: Cyclophosphamide 750mg/m2;   Drug: Vincristine 1.4mg/m2;   Drug: Doxorubicin 50mg/m2;   Drug: prednisone 60mg/m2;   Drug: ifosfamide 2000mg/m2;   Drug: pirarubicin 50mg/m2;   Drug: pirarubicin 25mg/m2;   Drug: Etoposide phosphate 100mg/m2;   Drug: methotrexate 1500mg/m2
36 Recruiting Safety Study of CPX-351 in Children With Relapsed Leukemia or Lymphoma
Conditions: Acute Myeloid Leukemia;   Acute Lymphoblastic Leukemia;   Burkitt Lymphoma;   Diffuse Large Cell Lymphoma;   'Grey Zone' Lymphoma;   Lymphoblastic Lymphoma;   Anaplastic Large Cell Lymphoma;   Hodgkin Lymphoma
Intervention: Drug: CPX-351
37 Recruiting SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
Conditions: CD-30 Positive Anaplastic Large T-cell Cutaneous Lymphoma;   Lymphoma, Primary Cutaneous Anaplastic Large Cell;   Lymphomatoid Papulosis;   Mycosis Fungoides;   Skin Lymphoma;   Cutaneous Lymphomas;   Lymphoma;   Hematologic Disorder
Intervention: Drug: SGN-35
38 Recruiting An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)
Conditions: Hodgkin Lymphoma,;   Mature T-cell Lymphoma;   Multiple Myeloma
Intervention: Drug: lenalidomide (Revlimid) and romidepsin (Istodax)
39 Recruiting Efficacy & Safety Study of Selinexor (KPT-330) in Relapsed/Refractory Peripheral T-cell Lymphoma & Cutaneous T-cell Lymphoma
Conditions: Peripheral T-cell Lymphoma (PTCL);   Cutaneous T-cell Lymphoma (CTCL)
Intervention: Drug: Selinexor
40 Recruiting EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma
Conditions: Lymphoma, Mantle Cell;   Mantle Cell Lymphoma
Interventions: Drug: EPOCH-R +/- Bortezomib;   Biological: Rituximab;   Drug: Bortezomib

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Indicates status has not been verified in more than two years